CAMP4 Therapeutics Corporation(CAMP)

Biotechnology · Cambridge, MA

$4.01+0.01 (+0.25%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T12:50:52.811Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:50:52.811Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 251,640,332
TTM free cash flow · period ending 2026-06-30: -28,720,000

FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAMP Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

CAMP Competitors' Price/FCF Ratio

CAMP

CAMP4 Therapeutics Corporation

Current

Market Cap

$251.64M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLSI

Greenwich LifeSciences, Inc.

vs CAMP

Market Cap

$248.21M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs CAMP

Market Cap

$247.45M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GALT

Galectin Therapeutics Inc.

vs CAMP

Market Cap

$245.65M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs CAMP

Market Cap

$244.25M

Price/FCF Ratio

6.08

TTM Avg

7.87

3Y Avg

7.87

5Y Avg

7.87

EPRX

Eupraxia Pharmaceuticals Inc.

vs CAMP

Market Cap

$259.30M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HITI

High Tide Inc.

vs CAMP

Market Cap

$239.89M

Price/FCF Ratio

20.91

TTM Avg

18.26

3Y Avg

16.59

5Y Avg

17.78

BIOA

BioAge Labs Inc.

vs CAMP

Market Cap

$239.45M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANIK

Anika Therapeutics, Inc.

vs CAMP

Market Cap

$264.05M

Price/FCF Ratio

469.83

TTM Avg

239.45

3Y Avg

256.85

5Y Avg

209.66

IKT

Inhibikase Therapeutics, Inc.

vs CAMP

Market Cap

$264.07M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
CAMP4 Therapeutics Corporation (CAMP)	$251.64M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$248.21M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$247.45M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$245.65M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$244.25M	6.08	7.87	7.87	7.87
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.30M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$239.89M	20.91	18.26	16.59	17.78
BioAge Labs Inc. (BIOA)vs ›	$239.45M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$264.05M	469.83	239.45	256.85	209.66
Inhibikase Therapeutics, Inc. (IKT)vs ›	$264.07M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

CAMP Price/FCF Ratio Metrics

CAMP Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics